PLCγ1

Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 Pipeline Review, H1 2017 Summary Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 Pipeline Review, H1 2017, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal downregulation of the expression of CYP7A1, the ratelimiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in PreRegistration, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 5, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer Cholangiocarcinoma, Type 2 Diabetes, Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Adenocarcinoma, Lymphoma, Melanoma, NonAlcoholic Steatohepatitis NASH, NonSmall Cell Lung Cancer, Obesity, Ovarian Cancer, Recurrent Glioblastoma Multiforme GBM, Adrenocortical Carcinoma Adrenal Cortex Cancer, Chronic Lymphocytic Leukemia CLL, Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Glioblastoma Multiforme GBM, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Metastatic Transitional Urothelial Tract Cancer, Nasopharyngeal Cancer, NonSmall Cell Lung Carcinoma, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, SmallCell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer and Transitional Cell Cancer Urothelial Cell Cancer. Furthermore, this report also reviewsalso reviews key players involved in Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 The report reviews Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities The report reviews key players involved in Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 targeted therapeutics and enlists all their major and minor projects The report assesses Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 targeted therapeutics Reasons to buy Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 Identify the use of drugs for target identification and drug repurposing Identify potential new clients or partners in the target demographic Develop strategic initiatives by understanding the focus areas of leading companies Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 development landscape Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope